Cerner Corporation’s CERN second-quarter 2018 results are scheduled to release on Aug 2, after market close. The company is likely to see a soft quarter owing to decline in the core Support, Maintenance and Services segment. However, growth in the company’s EHR (Electronic Health Record) platform is encouraging.In the last reported quarter, Cerner reported adjusted earnings per share of 58 cents per share, in line with the Zacks Consensus Estimate. However, earnings inched down 1.7% from the year-ago quarter. Revenues of $1.29 billion rose 2.6% year over year but missed the Zacks Consensus Estimate of $1.34 billion.For the second quarter, the Zacks Consensus Estimate for earnings is pegged at 60 cents, reflecting a year-over-year decline of 1.6%. The same for revenues is pinned at $1.33 billion, showing year-over-year growth of 2.7%.Cerner Corporation Price and EPS Surprise Cerner Corporation Price and EPS Surprise | Cerner Corporation QuoteInvestors must not forget that in the last reported quarter, Cerner reported under six segments instead of three. The segments are Licensed software, Subscriptions, Professional services, Managed services, Support and Maintenance and Reimbursed Travel.Let’s delve deeper.Support, Maintenance & Services in FocusIn the last reported quarter, this segment accounted for 22.1% of the company’s net sales. Revenues in the segment totaled $284.6 million, up 8.6% year over year. However, management stated that the segment witnessed low single-digit growth in the quarter.For the quarter to be reported, the Zacks Consensus Estimate is pegged at $881 million, showing a year-over-year fall of 3.9%.Thus, softness in the segment might offset the company’s revenue growth in the second quarter.Other Factors at PlaySystem Sales & Reimbursement TravelIn the quarter to be reported, Cerner’s two business units, System Sales and Reimbursement and Travel, are likely to disappoint.In the last reported quarter, Reimbursement and Travel contributed a mere 1.9% to net sales, while revenues in System Sales were not reported.For the quarter to be reported, the Zacks Consensus Estimate for Reimbursement and Travel stands at $25.5 million, down 4.7% from the prior-year quarter. The same for System Sales is pegged at $309 million, down 11.2% from the year-ago quarter.Guidance DownbeatCerner expects 2018 revenues in the range of $5.33-$5.45 billion, down from the previous range of $5.45 billion to $5.65 billion. Notably, the Zacks Consensus Estimate for revenues of $5.38 billion is within the guided range.For 2018, Cerner anticipates adjusted earnings per share of $2.45-$2.55, down from the prior guidance of $2.57-$2.73. The Zacks Consensus Estimate for 2018 earnings is pegged at $2.50 cents, within the projected range.Hence, possible declines in the core segments are likely to mar the company’s financials.For the second quarter of 2018, Cerner expects revenues in the range of $1.31-$1.36 billion. The Zacks Consensus Estimate for second-quarter revenues is pegged at $1.33 billion, within the projected range.EHR in FocusIn recent times, Cerner saw a slew of developments in its EHR front.The Missouri-based provider of healthcare technology solutions recently collaborated with Lumeris, an award-winning health plan and value-based care managed services operator. They aim to launch the new Maestro Advantage, for value-based arrangements, including Medicare Advantage (MA) and provider-sponsored health plans (PSHPs).Earlier this year, the company’s wholly owned subsidiary, Cerner Government Services, Inc. signed an agreement with the Department of Veterans Affairs (VA) with a view to facilitate care to the veteran community through VA’s efficient integrated network. (Read More: Cerner-VA Pact to Use EHR Platform for Better Veteran Service)What Our Model PredictsOur quantitative model does not conclusively show a beat for Cerner this earnings season. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates.Earnings ESP: Earnings ESP for Cerner is 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: Cerner carries a Zacks Rank #3.Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post a beat this earnings season.Edwards Lifesciences Corporation EW has an Earnings ESP of +0.59% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.Teleflex Incorporated TFX has an Earnings ESP of +0.27% and a Zacks Rank #3.PerkinElmer, Inc. PKI has an Earnings ESP of +1.03% and a Zacks Rank #3.Looking for Stocks with Skyrocketing Upside?Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.See the pot trades we're targeting>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cerner Corporation (CERN): Free Stock Analysis Report Teleflex Incorporated (TFX): Get Free Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here.